Choose a country to view content specific to your location
Choose a country to view content specific to your location
Liquid biopsy is a non-invasive alternative to tissue biopsy based on ultra-sensitive detection of tumor-derived material such as ctRNA and ctDNA from biofluids, including blood, urine, stool, saliva, and sputum. qPCR based liquid biopsy possesses several advantages in cost and throughput, when compared to other technologies like NGS and ddPCR. In this talk, we will discuss Meridian’s new advances in inhibitor tolerant qPCR based liquid biopsy, that reduces the cost and complexity of these assays, while enabling ultra-sensitive detection from very low concentration cancer markers.
Presenters
Steve Hawkins
Ph.D. – Product Marketing Manager
Michele Amasio, Ph.D.
Research and Development Senior Manager
The COVID-19 pandemic accelerated the adoption of point-of-care molecular technologies that offer quick sample to results, high sensitivity, lower cost and widespread accessibility.
This webinar will cover new market-leading reagent solutions for loop-mediated isothermal amplification (LAMP) assays, which simplify assay development, speed up assay turnaround time, and deliver highly sensitive and specific amplification without DNA or RNA extraction.
Presenters
Elda Iljazi Ph.D.
Senior Scientist Meridian Bioscience
The molecular diagnostic approach for infectious disease such as STDs, tropical, and respiratory disease has seen significant development in the past twelve months, driven by a demand for better, faster, higher sensitivity assays, that can detect asymptomatic carriers. Traditionally, lab-based tests using blood samples have been the mainstay for molecular testing, however home-based, extraction-free tests, using alternative sample types (saliva, urine, stool) are now highly sought after, but pose significant challenges in assay development for both lab-based and point of care (POC) applications.
In this webinar you will learn about:
Presenters
Michele Amasio, Ph.D.
Research and Development Senior Manager
Steve Hawkins
Ph.D. – Product Marketing Manager
Immunoassay interference can cause false-positive and false-negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA are the most prevalent and are identified in up to 25% of the patient population. Combined with HA, they represent the most significant factors leading to false positive immunoassay results.
Avoiding immunoassay interference requires blockers to be included in every immunoassay. Historically, animal-based interference blockers have been used to improve assay accuracy; however, they are susceptible to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages – as seen during the COVID-19 pandemic. Meridian’s new animal-free commercial blockers, K-BlockTM and Mouse-FREE IgG, are the next-generation solution for blocking HAMA/RF/HA that overcomes the ethical concerns and supply problems in using animal-derived blockers.
In this webinar you will learn the advantages of using animal-free immunoassay blockers and their performance.
Speakers:
Ryan Hughes Ph.D., (Life Science Immunology Product Manager, Meridian Bioscience)
Andy Gaspar Ph.D., (Life Science Technical Operations and Development Manager, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
Liquid biopsy is fast becoming the method of choice for cancer diagnosis in the field of precision medicine, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure. Liquid biopsy utilizes bodily fluids such as blood, stool, urine and saliva to detect cancer biomarkers earlier than conventional methods such as tissue biopsy. It is also useful to screen for drug-resistant subpopulations, micro-metastases, minimum residual disease and disease relapse. The non-invasive approach of liquid biopsies enables samples to be taken easily and repeatedly over the course of a patient’s treatment, overcoming the inherent shortcomings and risks of surgical tissue biopsies. This panel discussion will review how liquid biopsy is opening up new avenues in cancer detection and continuous monitoring for personalized cancer treatment, as well as the screening of cancer markers for therapeutic resistance. Four industrial leaders in the field of molecular diagnostics will come together to discuss the current status of liquid biopsy for cancer screening, as well as how modern technologies are changing the landscape of cancer detection and CDx.
Panelists:
Chris Sale (CEO, Nonacus, UK)
Shidong Jia, PhD (CEO, Predicine, USA)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
Speakers:
Mihai-Nicolae Podaru, PhD (R&D Senior Scientist, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.
